OBJECTIVE: High-resolution optical coherence tomography can be used noninvasively to evaluate vaginal morphologic features, including epithelial thickness, to assess this protective barrier in transmission of sexually transmitted infections and to monitor tissue response to topical medications and hormonal fluctuations. We examined the use of optical coherence tomography to measure epithelial thickness noninvasively before and after topical treatment with a drug that causes epithelial thinning. STUDY DESIGN: Twelve female sheep were treated with intravaginal placebo (n = 4) or nonoxynol-9 (n = 8). Vaginal optical coherence tomography images were obtained before and 24 hours after treatment. Four sheep in the nonoxynol-9 group were also examined on days 3 and 7. Vaginal biopsies were obtained on the last examination day. Epithelial thickness was measured in optical coherence tomography images and in hematoxylin and eosin-stained histologic sections from biopsies. Statistical analysis was performed using analyses of variance (significance P < .05). RESULTS: Baseline optical coherence tomography epithelial thickness measurements were similar (85 ± 19 μm placebo, 78 ± 20 μm nonoxynol-9; P = .52). Epithelial thinning was significant after nonoxynol-9 (32 ± 22 μm) compared with placebo (80 ± 15 μm) 24 hours after treatment (P < .0001). In the 4 nonoxynol-9-treated sheep followed for 7 days, epithelial thickness returned to baseline by day 3, and increased significantly on day 7. Epithelial thickness measurements from histology were not significantly different than optical coherence tomography (P = .98 nonoxynol-9, P = .93 hydroxyethyl cellulose). CONCLUSION: Drug-induced changes in the epithelium were clearly detectable using optical coherence tomography imaging. Optical coherence tomography and histology epithelial thickness measurements were similar, validating optical coherence tomography as a noninvasive method for epithelial thickness measurement, providing an important tool for quantitative and longitudinal monitoring of vaginal epithelial changes.
OBJECTIVE: High-resolution optical coherence tomography can be used noninvasively to evaluate vaginal morphologic features, including epithelial thickness, to assess this protective barrier in transmission of sexually transmitted infections and to monitor tissue response to topical medications and hormonal fluctuations. We examined the use of optical coherence tomography to measure epithelial thickness noninvasively before and after topical treatment with a drug that causes epithelial thinning. STUDY DESIGN: Twelve female sheep were treated with intravaginal placebo (n = 4) or nonoxynol-9 (n = 8). Vaginal optical coherence tomography images were obtained before and 24 hours after treatment. Four sheep in the nonoxynol-9 group were also examined on days 3 and 7. Vaginal biopsies were obtained on the last examination day. Epithelial thickness was measured in optical coherence tomography images and in hematoxylin and eosin-stained histologic sections from biopsies. Statistical analysis was performed using analyses of variance (significance P < .05). RESULTS: Baseline optical coherence tomography epithelial thickness measurements were similar (85 ± 19 μm placebo, 78 ± 20 μm nonoxynol-9; P = .52). Epithelial thinning was significant after nonoxynol-9 (32 ± 22 μm) compared with placebo (80 ± 15 μm) 24 hours after treatment (P < .0001). In the 4 nonoxynol-9-treated sheep followed for 7 days, epithelial thickness returned to baseline by day 3, and increased significantly on day 7. Epithelial thickness measurements from histology were not significantly different than optical coherence tomography (P = .98 nonoxynol-9, P = .93 hydroxyethyl cellulose). CONCLUSION: Drug-induced changes in the epithelium were clearly detectable using optical coherence tomography imaging. Optical coherence tomography and histology epithelial thickness measurements were similar, validating optical coherence tomography as a noninvasive method for epithelial thickness measurement, providing an important tool for quantitative and longitudinal monitoring of vaginal epithelial changes.
Authors: Kathleen L Vincent; Brent A Bell; Susan L Rosenthal; Lawrence R Stanberry; Nigel Bourne; Yvonne T Cosgrove Sweeney; Dorothy L Patton; Massoud Motamedi Journal: Sex Transm Dis Date: 2008-03 Impact factor: 2.830
Authors: Samata Mehta; Hans Verstraelen; Kathelijne Peremans; Geert Villeirs; Simon Vermeire; Filip De Vos; Els Mehuys; Jean Paul Remon; Chris Vervaet Journal: Int J Pharm Date: 2012-01-13 Impact factor: 5.875
Authors: Julia K S Gallwas; Lisa Turk; Herbert Stepp; Susanna Mueller; Robert Ochsenkuehn; Klaus Friese; Christian Dannecker Journal: Lasers Surg Med Date: 2011-03 Impact factor: 4.025
Authors: Kathleen L Vincent; Nigel Bourne; Brent A Bell; Gracie Vargas; Alai Tan; Daniel Cowan; Lawrence R Stanberry; Susan L Rosenthal; Massoud Motamedi Journal: Sex Transm Dis Date: 2009-05 Impact factor: 2.830
Authors: Yong Zhu; Jamal Saada; Shrestha Bhawana; Sam Lai; Paula Villarreal; Richard Pyles; Massoud Motamedi; Gracie Vargas; Tom Moench; Kathleen L Vincent Journal: Biol Reprod Date: 2021-02-11 Impact factor: 4.285
Authors: Richard B Pyles; Kathleen L Vincent; Marc M Baum; Barry Elsom; Aaron L Miller; Carrie Maxwell; Tonyia D Eaves-Pyles; Guangyu Li; Vsevolod L Popov; Rebecca J Nusbaum; Monique R Ferguson Journal: PLoS One Date: 2014-03-27 Impact factor: 3.240